Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Nimodipine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 323Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Grace Therapeutics Hosts Virtual KOL Event on GTx-104
    Grace Therapeutics Hosts Virtual KOL Event on GTx-104

    30 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/30/2971646/0/en/Grace-Therapeutics-to-Host-Virtual-KOL-Event-on-GTx-104-in-aneurysmal-Subarachnoid-Hemorrhage-on-November-20-2024.html

    GLOBENEWSWIRE
    30 Oct 2024
    Share Share
    Acasti Completes Enrollment In GTX-104 Phase 3 STRIVE-ON
    Acasti Completes Enrollment In GTX-104 Phase 3 STRIVE-ON

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952856/0/en/Acasti-Announces-Completion-of-Patient-Enrollment-in-Pivotal-Phase-3-STRIVE-ON-Safety-Trial-of-GTX-104.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Acasti to Present at the Life Sciences Investor Forum
    Acasti to Present at the Life Sciences Investor Forum

    12 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/12/2945131/0/en/Acasti-to-Present-at-the-Life-Sciences-Investor-Forum.html

    GLOBENEWSWIRE
    12 Sep 2024
    Share Share
    Acasti To Participate In H.C. Wainwright Investment Conference
    Acasti To Participate In H.C. Wainwright Investment Conference

    05 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/05/2941525/0/en/Acasti-to-Participate-in-the-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html

    GLOBENEWSWIRE
    05 Sep 2024
    Share Share
    Annora Pharma's Generic Nimodipine Receives Approvals in US
    Annora Pharma's Generic Nimodipine Receives Approvals in US

    09 Jul 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216937

    FDA
    09 Jul 2024
    Share Share
    Amneal Pharms LLC’s Generic Nimodipine Receives Tentative Approval In US
    Amneal Pharms LLC’s Generic Nimodipine Receives Tentative Approval In US

    14 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216256

    FDA
    14 May 2024
    Share Share